Johnson & Johnson has officially launched Aponvie (aprepitant) injectable emulsion in select European markets, following recent regulatory approvals. Aponvie is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults, a common complication after surgery.

The product is designed to provide rapid and sustained relief with a single intravenous dose, offering an alternative to oral antiemetic therapies. The launch is part of Johnson & Johnson's ongoing commitment to expanding its anesthesia and perioperative care portfolio in Europe.

Healthcare professionals in Europe can now access Aponvie for eligible patients, supporting improved patient outcomes in surgical settings. For more information, visit the official Johnson & Johnson website.